UroGen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a report released on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock.

Separately, Oppenheimer cut their price objective on UroGen Pharma from $35.00 to $34.00 and set an outperform rating for the company in a research note on Friday, March 15th.

UroGen Pharma Trading Down 0.1 %

NASDAQ:URGN traded down $0.02 during trading hours on Thursday, hitting $13.64. 220,283 shares of the stock were exchanged, compared to its average volume of 336,623. UroGen Pharma has a 52-week low of $8.57 and a 52-week high of $24.13. The firm's fifty day moving average price is $16.79 and its 200 day moving average price is $14.70. The company has a market cap of $319.86 million, a P/E ratio of -3.66 and a beta of 1.07.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The business had revenue of $23.53 million during the quarter, compared to the consensus estimate of $22.30 million. Equities analysts expect that UroGen Pharma will post -3.59 EPS for the current fiscal year.

Insider Activity

In other news, insider Mark Schoenberg sold 3,789 shares of the company's stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total value of $59,638.86. Following the completion of the sale, the insider now directly owns 149,423 shares in the company, valued at $2,351,918.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Mark Schoenberg sold 3,789 shares of the company's stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total value of $59,638.86. Following the completion of the sale, the insider now directly owns 149,423 shares in the company, valued at $2,351,918.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 4,993 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total value of $78,589.82. Following the completion of the transaction, the general counsel now owns 18,824 shares of the company's stock, valued at $296,289.76. The disclosure for this sale can be found here. Insiders sold 20,782 shares of company stock worth $306,829 over the last ninety days. Corporate insiders own 11.13% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in URGN. Rice Hall James & Associates LLC grew its position in UroGen Pharma by 6.5% in the first quarter. Rice Hall James & Associates LLC now owns 107,990 shares of the company's stock worth $941,000 after acquiring an additional 6,631 shares during the period. Swiss National Bank lifted its stake in UroGen Pharma by 9.1% during the first quarter. Swiss National Bank now owns 47,900 shares of the company's stock worth $417,000 after purchasing an additional 4,000 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in UroGen Pharma by 30.8% during the first quarter. JPMorgan Chase & Co. now owns 81,867 shares of the company's stock worth $714,000 after purchasing an additional 19,280 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in UroGen Pharma by 11.9% during the first quarter. Bank of New York Mellon Corp now owns 67,486 shares of the company's stock worth $588,000 after purchasing an additional 7,197 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in UroGen Pharma during the first quarter worth $215,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.